Skip to main content
SpringerLink
Log in

Insulin Aspart

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Insulin aspart is a recombinant analogue of human insulin. Following subcutaneous insulin injection (0.15 to 0.2 U/kg), significantly higher serum insulin concentrations are achieved in a shorter time with insulin aspart than with human insulin. The subsequent decline in serum insulin concentrations is also more rapid with insulin aspart.

  • ▴ In healthy individuals undergoing euglycaemic glucose clamp testing, glucose infusion rates were higher and reached maximum concentrations significantly earlier after insulin aspart than after human insulin.

  • ▴ Interindividual variability in pharmacodynamic and pharmacokinetic parameters with insulin aspart was generally less than that with human insulin, whereas the intraindividual variability in these parameters was similar after each insulin.

  • ▴ In patients with type 1 diabetes postprandial glucose excursions were less pronounced with insulin aspart than human insulin. Daytime glucose control was better and minimum glucose levels during the night were not as low with insulin aspart as with human insulin.

  • ▴ In diabetic patients treated with insulin aspart there was generally a lower frequency of hypoglycaemic events than in patients treated with human insulin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Drejer K, Kruse V, Larsen UD, et al. Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 1991 Nov; 40: 1488–95

    Article  PubMed  CAS  Google Scholar 

  2. Volund A, Brange J, Drejer K, et al. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 1991 Nov; 8: 839–47

    Article  PubMed  CAS  Google Scholar 

  3. Bornfeldt KE, Gidlöf RA, Wasteson A, et al. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 1991 May; 34: 307–13

    Article  PubMed  CAS  Google Scholar 

  4. Drejer K. Bioactivity of insulin analogues. In: Berger M, Gries FA, editors. Frontiers in insulin pharmacology: international symposium, Hamburg. Stuttgart: Georg Thieme Verlag, 1993: 17–27

    Google Scholar 

  5. Heinemann L, Heise T, Jorgensen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 1993 Jul; 10: 535–9

    Article  PubMed  CAS  Google Scholar 

  6. Heinemann L, Kapitza C, Starke AAR, et al. Time-action profile of the insulin analogue B28Asp. Diabetic Med 1996 Jul; 13: 683–4

    Article  PubMed  CAS  Google Scholar 

  7. Heinemann L, Weyer C, Rave K, et al. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes 1997; 105: 140–4

    Article  PubMed  CAS  Google Scholar 

  8. Heinemann L, Weyer C, Rauhaus M. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998 Nov; 21(11): 1910–4

    Article  PubMed  CAS  Google Scholar 

  9. Home P, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol (In press)

  10. Kang S, Brange J, Burch A, et al. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10, AspB28) in healthy subjects. Diabetes Care 1991 Nov; 14: 1057–65

    Article  PubMed  CAS  Google Scholar 

  11. Lindholm A, McEwen J, Riis A. Significantly improved postprandial glycaemic control with the novel rapid-acting insulin aspart [abstract]. Diabetologia 1998 Aug; 41 Suppl. 1: A49

    Google Scholar 

  12. Wiefels K, Hübinger A, Dannehl K, et al. Insulinkinetic and-dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). Horm Metab Res 1995; 27: 421–4

    Article  PubMed  CAS  Google Scholar 

  13. Kang S, Creagh FM, Peters JR, et al. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10, AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 1991 Jul; 14: 571–7

    Article  PubMed  CAS  Google Scholar 

  14. Rosenfalck AM, Thorsby P, Kjems L, et al. Effects of the rapid-acting insulin analogue insulin aspart on postprandial glycaemic excursions compared to human soluble insulin actrapid given immediately or 30 minutes before a meal in insulin treated type 2 diabetes patients. Acta Diabetologica [abstract]. 1998; 35(4): 246

    Google Scholar 

  15. Lutterman J, Pijpers E, Netten P, et al. Glycaemic control in IDDM patients during one day with injection of human insulin or the insulin analogues insulin X14 and insulin X14(+Zn). In: Berger M, Gries F, editors. Frontiers in insulin pharmacology: international symposium, Hamburg. Stuttgart: Thieme Medical Publishers, 1993: 102–9

    Google Scholar 

  16. Jensen I, Kruse V, Larsen UD. Scintigraphic studies in rats: kinetics of insulin analogues covering wide range of receptor affinities. Diabetes 1991; 40(5): 628–32

    Article  PubMed  CAS  Google Scholar 

  17. Home P, Lindholm A, Hylleberg B. Improved glycemic control with insulin aspart — a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998 Nov; 21(11): 1904–9

    Article  PubMed  CAS  Google Scholar 

  18. Ewing FME, Frier BM. Comparison of the physiological and symptomatic responses to hypoglycaemia induced by human soluble insulin and the insulin analogue aspart in patients with type 1 diabetes [abstract]. Diabetic Med 1998; 15 Suppl. 2: S34

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Kerryn L. Simpson & Caroline M. Spencer

Authors
  1. Kerryn L. Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline M. Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kerryn L. Simpson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simpson, K.L., Spencer, C.M. Insulin Aspart. Drugs 57, 759–765 (1999). https://doi.org/10.2165/00003495-199957050-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957050-00013

Keywords

Search

Navigation